Serengen Email Formats

About Serengen

Serengen is an innovative company with a mission to make hit identification fast and serendipitous discovery accessible to everyone. Our services include screening of DNA encoded libraries (DELs), tailored to your individual projects. Our technology overcomes the limitations of traditional DELs by addressing 3 key issues: (1) chemistry, (2) design, and (3) approach. Chemistry Serengen has developed a new encoding strategy which removes the barriers of DNA-compatible chemistry. It also overcomes the limitations of traditional DEL chemistry, which has often resulted in non-druglike and intractable hits associated with laborious and costly hit follow-up and a high attrition rate. Our technology allows us to choose from a variety of compatible chemical reactions which yield druglike and tractable compounds. Our DEL hits can be fed directly into lead generation, bypassing the costly and time-consuming hit follow-up process. Design Traditional DEL synthesis is limited by chemistry, but with Serengen's unique DEL technology we can harness the power of chemistry and the creativity of the chemist. A multitude of chemical reactions gives us unparalleled flexibility in DEL design, allowing us to venture into new chemical spaces and address new biological targets. With our unrivalled ability to create diversity through chemical reactions, we are pushing the boundaries of biochemistry and drug discovery. Approach We only use building blocks relevant to drug discovery and eliminate redundancies, reducing costs and time spent on hit follow-up. Our dual purification removes by-products and artifacts, reducing false positives. And our concentration adjustment reduces the risk of false negatives. Our Vision Our vision is to democratise drug discovery so that anyone striving to develop breakthrough drugs can afford the best possible chemical starting point. Book a meeting https://calendly.com/serengen to find out more about Serengen.

View contact profiles from Serengen